Previous studies have shown that AT1R blockade by ARBs improves cognitive impairment in various models of brain inflammation (Khallaf et al., 2017; Quiñones et al., 2016; Villapol et al., 2015; Wincewicz & Braszko, 2015). Here, AGTR1 is linked to brain inflammatory disease.